Telehealth prescribing is legal in all 50 states — but the details of how that prescribing can happen, who can do it, and what follow-up is required vary enormously. In 2026, as GLP-1 telehealth faces increased regulatory scrutiny, state medical boards are tightening requirements in ways that directly affect your access and your provider's compliance.
Some states now require that contraindication screening and informed consent happen at the same visit as the prescription. Others are mandating follow-up visits at defined intervals. And a growing number are retroactively auditing telehealth prescribers — not just reviewing new practices, but examining past prescribing patterns for compliance.
The Federal Framework
At the federal level, the Ryan Haight Act governs online prescribing of controlled substances. GLP-1 medications (semaglutide, tirzepatide) are not controlled substances, so the Ryan Haight Act doesn't directly apply to their prescribing. This is why telehealth platforms can prescribe GLP-1s through asynchronous (non-video) consultations in many states — a process that wouldn't be legal for controlled substances.
However, some states apply controlled-substance-level prescribing standards to all telehealth prescriptions, effectively requiring a synchronous (live video or phone) consultation before any new prescription — including GLP-1s.
Where Requirements Are Tightening
State medical boards are paying attention to the GLP-1 telehealth explosion, and several patterns are emerging:
Prescriber-patient relationship standards: Multiple states are clarifying or tightening what constitutes a legitimate prescriber-patient relationship in the telehealth context. A five-question asynchronous intake form reviewed by an NP in a different state may not meet the standard your state board expects — even if it's technically legal under the most permissive interpretation.
Informed consent requirements: States are increasingly requiring that patients receive explicit informed consent — in writing — about the fact that compounded medications are not FDA-approved, about the specific risks of GLP-1 therapy, and about the limitations of telehealth evaluation. Some states require this consent to be documented at the same visit as the prescription.
Follow-up mandates: The most consequential trend. State boards are beginning to specify minimum follow-up intervals for ongoing prescriptions. While not yet universal, the direction is clear: prescribing a GLP-1 with no required follow-up is becoming increasingly difficult to defend.
Collaborative practice agreement scrutiny: In states where nurse practitioners prescribe under collaborative practice agreements with physicians, boards are examining whether those agreements provide adequate oversight for GLP-1 prescribing specifically.
How to Verify Your Provider's State Compliance
- Check prescriber licensing: Your prescriber should be licensed in your state (the patient's state), not just the state where the platform is headquartered. You can verify this through your state medical board's online license lookup.
- Confirm the consultation type: Was your evaluation synchronous (live video or phone) or asynchronous (questionnaire only)? Some states require synchronous for initial prescriptions.
- Review your informed consent documentation: Did you sign or acknowledge a specific informed consent form? Can you access a copy? If you can't find one, you may not have received one.
- Ask about follow-up requirements: What follow-up schedule does your provider maintain? Is it aligned with your state's expectations?
- Verify pharmacy licensing: The pharmacy compounding or dispensing your medication should be licensed in both the state where it operates and the state where you receive the medication.